China Tongfu (01763) Affiliated Atomic Hi-Tech participated in the “Establishment of a Multimodal Nuclear Medical Molecular Imaging System for Childhood Neuroblastoma” project and won the first prize of the Beijing Medical Science and Technology Award

Zhitong Finance App News, China (01763) issued an announcement. Recently, the “Establishment of a Multi-modal Nuclear Medical Molecular Imaging System for Childhood Neuroblastoma” project completed with the participation of Atomic Hi-Tech Co., Ltd. (hereinafter referred to as Atom Hi-Tech) won the first prize of this year's Beijing Medical Science and Technology Award.

According to data released by Beijing Friendship Hospital affiliated to Capital Medical University (hereinafter referred to as Friendship Hospital), neuroblastoma is the most common extracranial solid tumor in children. The incidence rate is about 8% to 10% of malignant tumors in children, but it causes about 10% to 15% of childhood tumor-related deaths. More than half of the patients were classified as high-risk at the time of initial diagnosis. The prognosis was poor, and the 5-year survival rate was less than 50%. Due to its high incidence rate, high recurrence rate, and high mortality rate, the disease is called the “King of Childhood Cancers” by the medical community. It is not only a serious challenge in clinical diagnosis and treatment, but has also become a major public health issue affecting the health of children in China. With “the king of childhood cancer”, neuroblastoma, as a key breakthrough, the project closely revolves around the country's strategic deployment in the field of prevention and treatment of major and rare diseases in children. Relying on multi-modal nuclear medical molecular imaging technology, the project focused on the core bottlenecks of accurate neuroblastoma diagnosis and treatment. After ten years of systematic research, it successfully built a complete independent innovation chain from key equipment and core drugs to clinical application, forming a “multimodal, low-dose, short-course” neuroblastoma accurate diagnosis and treatment system with Chinese characteristics, contributing to the world's difficult problem With Chinese wisdom and China plan.

This project was completed under the leadership of Friendship Hospital. As the core lead unit for the innovative content of this project, “Research and development of nuclide drugs,” Atom Hi-Tech has carried out long-term and extensive work in neuroblastocyte nuclide drug research and development. ^{Atomic Hi-Tech successfully developed the positronuclide drug fluorine [18F] sodium fluoride injection, completed phase III clinical trials and successfully registered and marketed, filling the gap in domestic bone imaging positron nuclide drugs; took the lead in completing the formulation of group standards for iodine [123 I] sodium solution nuclides, and worked with Friendship Hospital to provide a basis for standardized production of domestic nuclide drugs; completed the development and phase III clinical trials of the positronuclide drug gallium [68 Ga] dotebutane injection. It promoted research and development of neuroblastoma positron nuclide drugs; successfully conquered the preparation technology for iodine [123 I] benzguanidine injections.}

Atom Hi-Tech and the Nuclear Medicine Department of Friendship Hospital adhere to the concept of “industry-university-research-medical collaborative innovation” and have established a long-term and stable strategic partnership. ^{The two sides collaborated deeply in the supply of nuclide drugs, joint construction of scientific research platforms, and promotion of clinical trials, and joined forces to complete key tasks such as technical research on the preparation of iodine [123 I] benzguanidine, and clinical trials of sodium fluoride [18 F] and gallium [68 Ga] docetane, laying a solid foundation for the implementation of project results.} In the future, Atomic Technology will continue to be deeply involved in the field of nuclear medicine, focus on the diagnosis and treatment needs of major diseases, increase investment in nuclide drug research and technology innovation, deepen cooperation with clinical institutions, help the development of precision medicine with better products and services, and build a firmer barrier to protecting people's health.